Jeff's career spans nearly 20 years in venture capital and early stage technology venture development. Jeff is a founding Board Member of C-PATH Institute, a startup non profit institute co-founded by the FDA, University of Arizona, and SRI International to develop research and educational programs to accelerate drug development. Jeff spent 16 years with Research Corporation Technologies, Inc. (RCT), a company engaged in early stage technology venture development and incubation, most recently as its Senior Vice President with oversight of RCT's Commercialization Group and responsibility for directing technology assessment and commercialization activities. At RCT, he managed the planning, creation and development of startup companies and was responsible for closure of licensing, fundraising, and venture creation activities. Jeff served as Chief Executive Officer for a number of RCT-based startup companies including Aeson Therapeutics, Inc. (cardiovascular and pulmonary disorders), MetaProbe, Inc. (MRI contrast agents), Paringenix, Inc. (anti inflammatory drugs), Advanced Pulmonary Therapeutics, LLC (respiratory disease), Salpep Biotechnology (respiratory disease). Additionally, he served on the board of Therapeutic Human Polyclonals, Inc. (anti infectives and immune disorders), CryoFluor Therapeutics LLC (medical devices for female health), Sertoli Technologies, Inc (cell therapy for diabetes), and Fullerene International Corporation (JV with Mitsubishi Corporation developing fullerenes). Jeff has a Masters degree in Engineering and a Masters degree in Technology and Policy from Massachusetts Institute of Technology as well as a Bachelors degree in Engineering from the University of Arizona.